In " Beyond Diagnosis: Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue ...

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ...

For patients with relapsed or refractory multiple myeloma, teclistamab monotherapy significantly improves progression-free ...

Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in ...

Teclistamab (Tecvayli; Johnson & Johnson) appears poised to move into earlier lines of care as a monotherapy, as bispecific antibodies made big news in the treatment of blood cancers and disorders on ...

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall.  | Bristol Myers Squibb may have gone big in ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...

Multiple myeloma is a type of blood cancer that starts in your bone marrow. This is the soft, spongy tissue inside your bones that makes most of your blood cells. It includes plasma cells, which help ...

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses ...

Multiple myeloma is a type of blood cancer because it forms in plasma cells, a kind of white blood cell that creates antibodies. Multiple myeloma, sometimes called myeloma, is uncommon. About 1 in 132 ...